VIB

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Protealis specializes in the development of advanced seeds and seed technologies for legume crops, focusing on enhancing their adaptability to the European environment. The company aims to be a leading provider of germplasm for sustainable plant proteins in Europe. By integrating innovative breeding techniques and nitrogen fixation methods, Protealis seeks to maximize the potential of legume crops. Additionally, the company employs proprietary seed coatings to support farmers in addressing the protein deficit and to provide local sourcing solutions for an increasing number of producers in the meat and milk alternatives sector.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

Muna Therapeutics is a private biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying innovative medicines that preserve cognitive functions and enhance resilience in individuals affected by these conditions. By prioritizing the development of suitable therapeutics, Muna Therapeutics aims to improve recovery outcomes for patients suffering from neurodegenerative diseases.

Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.

Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.

Animab is a biotechnology company focused on enhancing livestock health through innovative solutions. The company specializes in developing monoclonal antibodies that mimic secretory IgA, a natural antibody found in colostrum and milk, to protect nursing animals. Animab's technology targets specific intestinal pathogens in livestock, particularly during the critical post-weaning stage for piglets, without disrupting the healthy microbiome. This approach aims to improve animal health, reduce costs, and promote sustainability in livestock production.

ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.

Montis Biosciences is a biotechnology company founded in 2020 and based in Meise, Belgium. The company focuses on developing innovative immune-oncology therapeutics that address the intersection of vascular dysfunction and immune suppression in the treatment of solid tumors. Montis Biosciences has created a proprietary target screening and assay platform aimed at modulating the interactions between tumor endothelial cells and perivascular macrophages. This research provides valuable insights into the cellular dynamics of these interactions, enabling the development of novel therapeutic strategies to enhance immune responses against various tumors.

MRM Health NV is a biopharmaceutical company based in Ghent, Belgium, specializing in the development of microbiome-based therapeutics aimed at treating metabolic diseases. Founded in early 2020 as a subsidiary of MRM Technologies N.V., the company focuses on innovative drug discovery, notably its lead candidate MH002, which targets Inflammatory Bowel Disease (IBD), encompassing conditions such as Ulcerative Colitis and Crohn's disease. MRM Health was established in collaboration with the Flemish Institute of Biotechnology, leveraging expertise in microbiome research to translate scientific discoveries into effective therapeutic applications.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Biotalys is an agricultural technology company based in Ghent, Belgium, founded in 2013. The company specializes in researching and developing biopesticides designed to control pests and diseases on crops and harvested products. Biotalys employs its proprietary Agrobody technology platform to create protein-based biocontrol solutions that combine the effectiveness of chemical pesticides with the safety profile of biologicals. These solutions are suitable for both pre- and post-harvest applications, aiming to provide a more sustainable and safer food supply. The company's technology platform generates products that enable targeted delivery and retention of active ingredients to prevent and control weeds, pests, and diseases.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.

Biotalys is an agricultural technology company based in Ghent, Belgium, founded in 2013. The company specializes in researching and developing biopesticides designed to control pests and diseases on crops and harvested products. Biotalys employs its proprietary Agrobody technology platform to create protein-based biocontrol solutions that combine the effectiveness of chemical pesticides with the safety profile of biologicals. These solutions are suitable for both pre- and post-harvest applications, aiming to provide a more sustainable and safer food supply. The company's technology platform generates products that enable targeted delivery and retention of active ingredients to prevent and control weeds, pests, and diseases.

Multiplicom is a company that specializes in the development of molecular diagnostics products specifically tailored for medical genetics. It manufactures molecular diagnostic kits that facilitate the collection of genetic information, allowing for early identification of congenital defects during pregnancy. By focusing on effective, affordable, and personalized medicine, Multiplicom aims to enhance patient care through advanced clinical laboratory-based tests. Its products are designed to empower healthcare providers and patients with critical genetic insights, contributing to more informed treatment decisions.

Biotalys is an agricultural technology company based in Ghent, Belgium, founded in 2013. The company specializes in researching and developing biopesticides designed to control pests and diseases on crops and harvested products. Biotalys employs its proprietary Agrobody technology platform to create protein-based biocontrol solutions that combine the effectiveness of chemical pesticides with the safety profile of biologicals. These solutions are suitable for both pre- and post-harvest applications, aiming to provide a more sustainable and safer food supply. The company's technology platform generates products that enable targeted delivery and retention of active ingredients to prevent and control weeds, pests, and diseases.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Multiplicom is a company that specializes in the development of molecular diagnostics products specifically tailored for medical genetics. It manufactures molecular diagnostic kits that facilitate the collection of genetic information, allowing for early identification of congenital defects during pregnancy. By focusing on effective, affordable, and personalized medicine, Multiplicom aims to enhance patient care through advanced clinical laboratory-based tests. Its products are designed to empower healthcare providers and patients with critical genetic insights, contributing to more informed treatment decisions.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of a new generation of biological drugs, utilizing a versatile and proprietary technology platform. This platform focuses on a delivery system that employs living non-pathogenic microorganisms for the oral administration of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, positioning itself at the forefront of innovative therapeutic solutions.

AlgoNomics is a Belgium-based biotechnology company specializing in structural bioinformatics services aimed at advancing the development of therapeutics in the field of immunotherapy. The company boasts a proprietary technology platform that includes advanced tools for analyzing protein-protein and protein-peptide interactions. Among its key offerings is the Epibase platform, which focuses on T-cell epitope identification across diverse population groups. This platform plays a crucial role in the discovery of vaccines and therapeutic proteins, facilitating immunogenicity screening to support the development of biotherapeutics. Through its innovative approach, AlgoNomics is positioned to make significant contributions to the biopharmaceutical industry.